A Pilot Study of Cyclophosphamide/Pegylated Liposomal Doxorubicin/Vincristine/Prednisone (CDOP) Plus Rituximab for Treatment of Elderly Patients With Previously Untreated Non-Hodgkin's Lymphoma
Elderly NHL patients tend to tolerate the combination of cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) less well when compared to the younger population.
Cardiotoxicity, as well as neutropenia, are the most common side effects in the elderly
population with age being a risk factor for doxorubicin induced cardiac toxicity. Treatment
related toxicity in the older population can preclude adequate therapy and potentially
contribute to poor outcomes. Pegylated liposomal doxorubicin has shown similar efficacy
with a significant lower incidence of cardiotoxicity ad significantly fewer cardiac events
compared with conventional doxorubicin. Exploration of alternative regimens to maximize
tolerability and thus enhance overall efficacy in this population is warranted. Both safety
and efficacy will be evaluated.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the feasibility and tolerability of CDOP plus rituximab in elderly patients with previously untreated NHL.
Lodovico Balducci, MD
Geriatric Oncology Consortium
United States: Institutional Review Board
|Fountain Valley, California 92708|
|Miami, Florida 33176|
|Hackensack, New Jersey 07601|
|Washington, District of Columbia|